9 June 2016 - The EMA has published an EPAR for Amicus Therapeutics' Galafold (migalastat hydrochloride).

Galafold was approved by the European Commission on 26 May 2016 for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004059/human_med_001981.jsp&mid=WC0b01ac058001d124